Suchergebnisse - "Calegari, Maria Alessandra"

PubPharm (33)

1

Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients : A Multicenter Retrospective Analysis

enthalten in: Targeted oncology | 2024

von Basso, M. | Signorelli, C. | Calegari, M. | +17

2

Focus on RAS Codon 61 Mutations in Metastatic Colorectal Cancer : A Retrospective Analysis

enthalten in: Cancers | 2024

von Schietroma, F. | Anghelone, A. | Valente, G. | +17

3

The impact of a multidisciplinary tumour board (MDTB) in the management of colorectal cancer (CRC)

enthalten in: ResearchSquare.com | 2024

von Schietroma, F. | Bensi, M. | Calegari, M. | +30

4

Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer : A Real-World Subgroup Analysis

enthalten in: Cancers | 2023

von Signorelli, C. | Chilelli, M. | Giannarelli, D. | +22

5

Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer : A systematic review and bayesian network meta-analysis

enthalten in: Critical reviews in oncology/hematology | 2023

von Mastrantoni, L. | Beccia, V. | Caira, G. | +8

6

Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis

enthalten in: Cancers | 2023

von Formica, V. | Morelli, C. | Conca, V. | +14

7

Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer : A Real-World Multicenter Retrospective Study

enthalten in: Current oncology (Toronto, Ont.) | 2023

von Signorelli, C. | Calegari, M. | Basso, M. | +21

8

Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients

enthalten in: Frontiers in oncology | 2023

von Salvatore, L. | Bensi, M. | Vivolo, R. | +11

9

Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients : does primary tumour location matter?

enthalten in: British journal of cancer | 2022

von Moretto, R. | Elliott, A. | Rossini, D. | +21

10

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer : The MAYA Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Morano, F. | Raimondi, A. | Pagani, F. | +30